Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes

Olga I. Isaeva(Skolkovo Institute of Science and Technology), Г. В. Шаронов(Privolzhsky Research Medical University), Ekaterina O. Serebrovskaya(Pirogov Russian National Research Medical University), Maria A. Turchaninova(Privolzhsky Research Medical University), Andrew R. Zaretsky(Pirogov Russian National Research Medical University), Mikhail Shugay(Privolzhsky Research Medical University), Dmitriy M. Chudakov(Privolzhsky Research Medical University)
Journal for ImmunoTherapy of Cancer
October 29, 2019
Cited by 101Open Access
Full Text

Abstract

BACKGROUND: The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita. In particular, it remains unexplored how driver mutations could be associated with distinct TIBs signatures and their role in tumor microenvironment. METHODS: Here we analyzed associations of immunoglobulin isotypes and clonality with survival in TCGA RNA-Seq data for lung adenocarcinoma (LUAD), stratifying patients into 12 driver mutation and phenotypic tumor subgroups. RESULTS: and proximal proliferative subgroups of LUAD patients. We hypothesize that the positive role of IgG4 antibodies in some of the lung cancer subtypes could be associated with reported inability of IgG4 isotype to form immune complexes, thus preventing immunosuppression via activation of the myeloid-derived suppressor cell (MDSC) phenotype. CONCLUSIONS: We discover prominent and distinct associations between TIBs antibody isotypes and survival in lung adenocarcinoma carrying specific driver mutations. These findings indicate that particular types of tumor-immunity relations could be beneficial in particular driver mutation context, which should be taken into account in developing strategies of cancer immunotherapy and combination therapies. Specificity of protective B cell populations in specific cancer subgroups could become a clue to efficient targeted immunotherapies for appropriate cohorts of patients.


Related Papers

No related papers found

Powered by citation graph analysis